Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study

Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis